Regarding the barrier of PD, the safe dosage in the human body, although high enough to modulate the established function in the existing indication (herein inducing M3 AML cell differentiation[38, 39]), maybe insufficient to modulate the desired function in the new indication (herein upregulating RIG‐I and triggering IFN immune response). The gene discussed is IFNA1; the disease is acute myeloid leukemia.